Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 597

1.

Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.

Youdim MBH.

J Neural Transm (Vienna). 2018 Nov;125(11):1719-1733. doi: 10.1007/s00702-018-1942-9. Epub 2018 Oct 19. Review.

PMID:
30341696
2.

A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.

Jacob TF, Singh V, Dixit M, Ginsburg-Shmuel T, Fonseca B, Pintor J, Youdim MBH, Major DT, Weinreb O, Fischer B.

Purinergic Signal. 2018 Sep;14(3):271-284. doi: 10.1007/s11302-018-9614-7. Epub 2018 Jul 17.

3.

Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.

Grünblatt E, Ruder J, Monoranu CM, Riederer P, Youdim MB, Mandel SA.

Neurotox Res. 2018 Apr;33(3):560-568. doi: 10.1007/s12640-017-9843-5. Epub 2017 Dec 7.

PMID:
29218503
4.

Iron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa.

Wang K, Peng B, Xiao J, Weinreb O, Youdim MBH, Lin B.

Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5287-5297. doi: 10.1167/iovs.17-22096.

PMID:
29049732
5.

Monoamine oxidase A upregulated by chronic intermittent hypoxia activates indoleamine 2,3-dioxygenase and neurodegeneration.

Lam CS, Li JJ, Tipoe GL, Youdim MBH, Fung ML.

PLoS One. 2017 Jun 9;12(6):e0177940. doi: 10.1371/journal.pone.0177940. eCollection 2017.

6.

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models.

Amit T, Bar-Am O, Mechlovich D, Kupershmidt L, Youdim MBH, Weinreb O.

Neuropharmacology. 2017 Sep 1;123:359-367. doi: 10.1016/j.neuropharm.2017.05.026. Epub 2017 May 29. Review.

PMID:
28571715
7.

The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.

Einoch R, Weinreb O, Mandiuk N, Youdim MBH, Bilker W, Silver H.

Eur Neuropsychopharmacol. 2017 May;27(5):470-483. doi: 10.1016/j.euroneuro.2017.03.005. Epub 2017 Apr 11.

PMID:
28410959
8.

Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells.

Liu W, Rabinovich A, Nash Y, Frenkel D, Wang Y, Youdim MBH, Weinreb O.

Neuropharmacology. 2017 Feb;113(Pt A):445-456. doi: 10.1016/j.neuropharm.2016.10.028. Epub 2016 Oct 28.

PMID:
27984078
9.

M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the Hippocampus.

Lam CS, Tipoe GL, Wong JK, Youdim MB, Fung ML.

PLoS One. 2016 Nov 21;11(11):e0166966. doi: 10.1371/journal.pone.0166966. eCollection 2016.

10.

A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice.

Golko-Perez S, Amit T, Bar-Am O, Youdim MB, Weinreb O.

Neurotox Res. 2017 Feb;31(2):230-244. doi: 10.1007/s12640-016-9677-6. Epub 2016 Nov 8.

PMID:
27826939
11.

N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic Change.

Shin EJ, Nam Y, Lee JW, Nguyen PT, Yoo JE, Tran TV, Jeong JH, Jang CG, Oh YJ, Youdim MBH, Lee PH, Nabeshima T, Kim HC.

Mol Neurobiol. 2016 Nov;53(9):6251-6269. doi: 10.1007/s12035-015-9527-1. Epub 2015 Nov 13.

PMID:
26563498
12.

Neurorescue by a ROS Decomposition Catalyst.

Soll M, Bar Am O, Mahammed A, Saltsman I, Mandel S, Youdim MB, Gross Z.

ACS Chem Neurosci. 2016 Oct 19;7(10):1374-1382. Epub 2016 Aug 5.

PMID:
27442690
13.

Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease.

Liu W, Lang M, Youdim MBH, Amit T, Sun Y, Zhang Z, Wang Y, Weinreb O.

Neuropharmacology. 2016 Oct;109:376-385. doi: 10.1016/j.neuropharm.2016.06.013. Epub 2016 Jun 16.

PMID:
27318273
14.

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.

Unzeta M, Esteban G, Bolea I, Fogel WA, Ramsay RR, Youdim MB, Tipton KF, Marco-Contelles J.

Front Neurosci. 2016 May 25;10:205. doi: 10.3389/fnins.2016.00205. eCollection 2016. Review.

15.

Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS Mice.

Golko-Perez S, Amit T, Youdim MB, Weinreb O.

J Mol Neurosci. 2016 Aug;59(4):504-10. doi: 10.1007/s12031-016-0763-2. Epub 2016 May 13.

PMID:
27173029
16.

Binge ethanol exposure increases the Krüppel-like factor 11-monoamine oxidase (MAO) pathway in rats: Examining the use of MAO inhibitors to prevent ethanol-induced brain injury.

Duncan JW, Zhang X, Wang N, Johnson S, Harris S, Udemgba C, Ou XM, Youdim MB, Stockmeier CA, Wang JM.

Neuropharmacology. 2016 Jun;105:329-340. doi: 10.1016/j.neuropharm.2016.01.024. Epub 2016 Jan 22.

17.

Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis.

Golko-Perez S, Mandel S, Amit T, Kupershmidt L, Youdim MB, Weinreb O.

Neurotox Res. 2016 Feb;29(2):208-17. doi: 10.1007/s12640-015-9574-4. Epub 2015 Nov 18.

PMID:
26581376
18.

The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease.

Pimentel LS, Allard S, Do Carmo S, Weinreb O, Danik M, Hanzel CE, Youdim MB, Cuello AC.

J Alzheimers Dis. 2015;47(2):373-83. doi: 10.3233/JAD-143126.

PMID:
26401560
19.

Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Br J Pharmacol. 2016 Jul;173(13):2080-94. doi: 10.1111/bph.13318. Epub 2015 Dec 1. Review.

20.

Phosphorylation of CHIP at Ser20 by Cdk5 promotes tAIF-mediated neuronal death.

Kim C, Yun N, Lee J, Youdim MB, Ju C, Kim WK, Han PL, Oh YJ.

Cell Death Differ. 2016 Feb;23(2):333-46. doi: 10.1038/cdd.2015.103. Epub 2015 Jul 24.

21.

Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease.

Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smailovic U, Trkulja V, Riederer P, Amit T, Mandel S, Youdim MB.

Life Sci. 2015 Sep 1;136:108-19. doi: 10.1016/j.lfs.2015.06.026. Epub 2015 Jul 6.

PMID:
26159898
22.

Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice.

Weinreb O, Badinter F, Amit T, Bar-Am O, Youdim MB.

Neurobiol Aging. 2015 Sep;36(9):2628-36. doi: 10.1016/j.neurobiolaging.2015.05.009. Epub 2015 May 21.

PMID:
26142126
23.

Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice.

Badinter F, Amit T, Bar-Am O, Youdim MB, Weinreb O.

Neuropharmacology. 2015 Dec;99:264-72. doi: 10.1016/j.neuropharm.2015.05.041. Epub 2015 Jun 15.

PMID:
26087462
24.

Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.

Bar-Am O, Amit T, Youdim MB, Weinreb O.

J Neural Transm (Vienna). 2016 Feb;123(2):125-35. doi: 10.1007/s00702-015-1395-3. Epub 2015 Apr 10. Review.

PMID:
25859841
25.

A novel antioxidant multitarget iron chelator M30 protects hepatocytes against ethanol-induced injury.

Xiao J, Lv Y, Lin B, Tipoe GL, Youdim MB, Xing F, Liu Y.

Oxid Med Cell Longev. 2015;2015:607271. doi: 10.1155/2015/607271. Epub 2015 Feb 4.

26.

Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.

Bar-Am O, Amit T, Kupershmidt L, Aluf Y, Mechlovich D, Kabha H, Danovitch L, Zurawski VR, Youdim MB, Weinreb O.

Neurobiol Aging. 2015 Mar;36(3):1529-42. doi: 10.1016/j.neurobiolaging.2014.10.026. Epub 2014 Oct 22.

PMID:
25499799
27.

Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus.

Mechlovich D, Amit T, Bar-Am O, Weinreb O, Youdim MB.

Br J Pharmacol. 2014 Dec;171(24):5636-49. doi: 10.1111/bph.12862.

28.

Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.

Wang L, Esteban G, Ojima M, Bautista-Aguilera OM, Inokuchi T, Moraleda I, Iriepa I, Samadi A, Youdim MB, Romero A, Soriano E, Herrero R, Fernández Fernández AP, Ricardo-Martínez-Murillo, Marco-Contelles J, Unzeta M.

Eur J Med Chem. 2014 Jun 10;80:543-61. doi: 10.1016/j.ejmech.2014.04.078. Epub 2014 Apr 29.

PMID:
24813882
29.

Regional siderosis: a new challenge for iron chelation therapy.

Cabantchik ZI, Munnich A, Youdim MB, Devos D.

Front Pharmacol. 2013 Dec 31;4:167. doi: 10.3389/fphar.2013.00167. Review.

30.
31.

DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline.

Trudler D, Weinreb O, Mandel SA, Youdim MB, Frenkel D.

J Neurochem. 2014 May;129(3):434-47. doi: 10.1111/jnc.12633. Epub 2014 Jan 6.

32.

Impaired autophagic flux is critically involved in drug-induced dopaminergic neuronal death.

Lim J, Lee Y, Jung S, Youdim MB, Oh YJ.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S162-6. doi: 10.1016/S1353-8020(13)70039-7.

PMID:
24262172
33.

Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.

Youdim MB, Kupershmidt L, Amit T, Weinreb O.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S132-6. doi: 10.1016/S1353-8020(13)70032-4. Review.

PMID:
24262165
34.

Gel-based protease proteomics for identifying the novel calpain substrates in dopaminergic neuronal cell.

Kim C, Yun N, Lee YM, Jeong JY, Baek JY, Song HY, Ju C, Youdim MB, Jin BK, Kim WK, Oh YJ.

J Biol Chem. 2013 Dec 20;288(51):36717-32. doi: 10.1074/jbc.M113.492876. Epub 2013 Nov 14.

35.

Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy.

Youdim MB, Oh YJ.

Exp Neurobiol. 2013 Sep;22(3):167-72. doi: 10.5607/en.2013.22.3.167. Epub 2013 Sep 30. Review.

36.
37.

Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.

Weinreb O, Mandel S, Youdim MBH, Amit T.

Free Radic Biol Med. 2013 Sep;62:52-64. doi: 10.1016/j.freeradbiomed.2013.01.017. Epub 2013 Jan 30. Review.

PMID:
23376471
38.

Lithium's gene expression profile, relevance to neuroprotection A cDNA microarray study.

Farah R, Khamisy-Farah R, Amit T, Youdim MB, Arraf Z.

Cell Mol Neurobiol. 2013 Apr;33(3):411-20. doi: 10.1007/s10571-013-9907-x. Epub 2013 Jan 17.

PMID:
23324999
39.

I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline.

Barac YD, Bar-Am O, Liani E, Amit T, Frolov L, Ovcharenko E, Angel I, Youdim MB, Binah O.

PLoS One. 2012;7(11):e47890. doi: 10.1371/journal.pone.0047890. Epub 2012 Nov 15. Erratum in: PLoS One. 2013;8(6). doi: 10.1371/annotation/9dae97ef-4a68-47b2-a8f5-fb953ebe877c.

40.

Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.

Kupershmidt L, Amit T, Bar-Am O, Weinreb O, Youdim MB.

Mol Neurobiol. 2012 Aug;46(1):217-20. doi: 10.1007/s12035-012-8304-7. Epub 2012 Jul 31.

PMID:
22847630
41.

In the rush for green gold: Can green tea delay age-progressive brain neurodegeneration?

Mandel SA, Youdim MB.

Recent Pat CNS Drug Discov. 2012 Dec;7(3):205-17. Review.

PMID:
22742421
42.

Neuroprotection and neuroregeneration in Alzheimer's disease.

Sugaya K, Youdim MB, Nordberg A, Rao KS.

Int J Alzheimers Dis. 2012;2012:864138. doi: 10.1155/2012/864138. Epub 2012 Jun 11. No abstract available.

43.

Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death.

Kim SJ, Park YJ, Hwang IY, Youdim MB, Park KS, Oh YJ.

Free Radic Biol Med. 2012 Aug 15;53(4):936-50. doi: 10.1016/j.freeradbiomed.2012.05.035. Epub 2012 Jun 7.

PMID:
22683601
44.

Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.

Zheng H, Fridkin M, Youdim MB.

Curr Drug Targets. 2012 Jul;13(8):1089-106. Review.

PMID:
22676912
45.

A molecular signature in blood identifies early Parkinson's disease.

Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grünblatt E, Riederer P, Jacob C, Aharon-Peretz J, Bashenko Y, Youdim MB, Mandel SA.

Mol Neurodegener. 2012 May 31;7:26. doi: 10.1186/1750-1326-7-26.

46.

Psychiatric, nonmotor aspects of Parkinson's disease.

Müller T, Gerlach M, Youdim MB, Riederer P.

Handb Clin Neurol. 2012;106:477-90. doi: 10.1016/B978-0-444-52002-9.00028-0. Review. No abstract available.

PMID:
22608639
47.

Social-cooperation differs from individual behavior in hypothalamic and striatal monoamine function: evidence from a laboratory rat model.

Tsoory MM, Youdim MB, Schuster R.

Behav Brain Res. 2012 Jun 15;232(1):252-63. doi: 10.1016/j.bbr.2012.04.032. Epub 2012 Apr 26.

PMID:
22561126
48.

Nigericin-induced impairment of autophagic flux in neuronal cells is inhibited by overexpression of Bak.

Lim J, Lee Y, Kim HW, Rhyu IJ, Oh MS, Youdim MB, Yue Z, Oh YJ.

J Biol Chem. 2012 Jul 6;287(28):23271-82. doi: 10.1074/jbc.M112.364281. Epub 2012 Apr 5.

49.

Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease.

Arraf Z, Amit T, Youdim MB, Farah R.

Neurosci Lett. 2012 May 10;516(1):57-61. doi: 10.1016/j.neulet.2012.03.055. Epub 2012 Mar 28.

PMID:
22480690
50.

Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.

Pollak Y, Mechlovich D, Amit T, Bar-Am O, Manov I, Mandel SA, Weinreb O, Meyron-Holtz EG, Iancu TC, Youdim MB.

J Neural Transm (Vienna). 2013 Jan;120(1):37-48. doi: 10.1007/s00702-012-0795-x. Epub 2012 Mar 25.

PMID:
22446839

Supplemental Content

Loading ...
Support Center